Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy
© Zeh et al.; licensee BioMed Central Ltd. 2013
Received: 10 September 2012
Accepted: 8 February 2013
Published: 12 February 2013
Malignant transformation describes the phenomenon in which a somatic component of a germ cell teratoma undergoes malignant differentiation. A variety of different types of sarcoma and carcinoma, all non-germ cell, have been described as a result of malignant transformation.
A 33-year-old man presented with a left testicular mass and elevated tumour markers. Staging investigations revealed retroperitoneal lymphadenopathy with obstruction of the left ureter and distant metastases. Histopathology from the left radical orchiectomy showed a mixed germ cell tumour (Stage III, poor prognosis). The ureter was stented and four cycles of cisplatin, etoposide and bleomycin chemotherapy administered. After initial remission, the patient recurred four years later with a large retroperitoneal mass involving the renal vessels and the left ureter. Left retroperitoneal lymph node dissection with en-bloc resection of the left kidney was performed.
Histopathology revealed a germ cell tumour metastasis consisting mainly of mature teratoma. Additionally, within the teratoma a papillary renal cell carcinoma was found. The diagnosis was supported by immunohistochemistry showing positivity for AMACR, CD10 and focal expression of RCC and CK7. There was no radiological or histo-pathological evidence of a primary renal cell cancer.
To the best of our knowledge, malignant transformation into a papillary renal cell carcinoma has not been reported in a testicular germ cell tumour metastasis following platinum-based chemotherapy. This histological diagnosis might have implications for potential future therapies. In the case of disease recurrence, renal cell cancer as origin of the recurrent tumour has to be excluded because renal cell carcinoma metastases would not respond well to the classical germ cell tumour chemotherapy regimens.
KeywordsRetroperitoneal teratoma Malignant transformation Germ cell tumour metastasis Renal cell cancer
Teratoma is a tumour of embryonic origin and belongs to the group of non-seminomatous germ cell tumours (GCT) . Primarily, it occurs most often in the testis or ovary but may also appear in other body sites such as the central nervous system, mediastinum or retroperitoneum . Non-seminomatous GCT can be pure teratoma but mixed forms with other non-seminomatous histologies occur more frequently. However, teratoma is often the only component that remains histologically detectable in residual lesions after platinum-based chemotherapy for metastatic mixed non-seminomatous GCT.
Teratoma typically contains different types of tissue derived from all three germinal layers, the endoderm, mesoderm and ectoderm. It can be of cystic or solid appearance and depending on the degree of differentiation seen it is classified as mature or immature teratoma . The immature form is characterised by somatic differentiated cells in an early ‘embryonal’ stage. A mature teratoma consists of fully differentiated somatic tissues such as cartilage, epidermis, nerve tissue, glands or even complex organs. Mature renal tissue has rarely been reported to be a part of mature teratoma .
Somatic malignant transformation (MT) refers to malignant de-differentiation of teratoma components . It is a well-described phenomenon, characterized by differentiation of pluripotent teratoma cells into somatic tumour cells [2, 4–7]. Usually MT occurs in adult patients with metastatic GCT disease and can arise either in the primary or metastatic site of the tumour . Sarcoma is the most frequently described malignant histology but a variety of other tumour entities including enteric adenocarcinoma, primitive neuroectodermal tumour (PNET) and leukaemia have also been found [2, 4–6]. To the best of our knowledge, MT into papillary renal cell cancer has never been reported in a testicular GCT metastasis following platinum-based chemotherapy.
A 33-year-old man presented with a left-sided, painless scrotal mass suspicious for testicular cancer. Scrotal ultrasound showed a 3 cm mass of heterogeneous echogenicity in the left testicle with irregular, poorly defined borders. Serum tumour markers were elevated with an alpha-fetoprotein (AFP) of 28135 μg/l, beta-human chorionic gonadotropin (ß-HCG) of 19700 U/l and lactate dehydrogenase (LDH) of 4421 U/l. Staging thoraco-abdominal computed tomography (CT) showed bulky retroperitoneal lymphadenopathy, left hydronephrosis, metastases to both liver and lung, as well as mediastinal and supraclavicular lymphadenopathy.
The patient underwent left inguinal orchiectomy and routine biopsy of the contra-lateral testis in a secondary referral centre. A double-J stent was inserted into the left ureter.
Histo-pathological examination of the left testis revealed a mixed GCT consisting of two-thirds classical seminoma and one-third non-seminomatous tumour with embryonal carcinoma and yolk sac tumour components. In the adjacent parenchyma intra-tubular germ cell neoplasia was found. The right testis biopsy showed normal testicular tissue without intra-tubular germ cell neoplasia. The tumour stage was determined to be pT1 cN3 cM1b S3 (TNM; ) and clinical stage IIIC poor prognosis group (Lugano classification; ).
Left retroperitoneal lymphadenectomy with en-bloc resection of the left kidney and the infrarenal aorta was performed. An aorto-bi-iliacal graft was inserted.
Immunohistochemistry showed strong positivity for alpha-methylacyl-CoA racemase (AMACR, Figure 3c), CD 10 (not shown), focal expression of renal cell carcinoma antigen (RCC; Figure 3d) and cytokeratin 7 (CK 7; not shown). Vimentin and AFP were negative (not shown). Histologically, no renal cell cancer was found in the removed left kidney.
No additional chemotherapy was administered after surgery. Currently, 2 years after retroperitoneal lymphadenectomy, the patient remains progression-free with stable disease showing no further tumour growth, metabolic PET-activity or tumour marker elevation.
Somatic MT develops in 3-6% of chemotherapy-naïve patients with metastatic GCT containing teratomous components [4, 9]. After platinum-based chemotherapy the incidence of MT increases up to 14% . Histologically, various types of sarcoma and carcinoma have been identified in GCT with MT. The most commonly MTs reported are rhabdomyosarcoma, PNET and adenocarcinoma. Leiomyosarcoma, liposarcoma, chondrosarcoma, Non-Hodgkin’s lymphoma and leukaemia are found less frequently [2, 3, 6]. Renal tumour differentiation is rare. Nephroblastoma (Wilms tumour) have been described  and there is a single report of MT into papillary renal cell carcinoma in a primary retroperitoneal and chemotherapy-naïve GCT . To the best of our knowledge, MT into papillary renal cell cancer within a testicular GCT metastasis following platinum-based chemotherapy has not been previously documented.
It is highly unlikely that the papillary renal cell cancer found was a metastasis originating from the kidneys. We believe the papillary renal cell carcinoma resulted from MT of the teratoma for several reasons. Firstly, the lesion was located within the teratoma. Secondly, both kidneys had normal appearance on multiple abdominal CTs and FDG-PET. Finally, there was no histological evidence of renal cell cancer in the left kidney that was removed en bloc. There was also no family history of papillary renal cell cancer. In cases with more clinical ambiguity, fluorescence in situ hybridisation (FISH) analysis for 12p amplification can be used to confirm the germ-cell origin of somatic-type tumours of uncertain histogenesis .
The characteristic morphology and the immunohistochemical profile confirmed the diagnosis of papillary renal cell cancer. Papillary renal cell cancer is differentiated from other subtypes of renal cell cancer by using CK7 and AMACR immunohistochemical markers . Most papillary renal cell carcinomas are positive for CK7, whereas clear cell renal cell cancer shows either negative or only a focal or expression pattern . A panel of immunohistochemical markers, including CD10, RCC, and vimentin, has been proposed for the identification of renal origin of a metastatic tumour [12, 14]. Identification of the most common chromosomal aberrations in papillary renal cell cancer (trisomy of chromosome 7 and 17 as well as loss of Y chromosome ) were not necessary in our case due to convincing histological and immunohistochemical features.
The role of FDG-PET in evaluating residual masses after chemotherapy differs between seminomatous and non-seminomatous GCTs . FDG-PET can discriminate between viable tumour and fibrosis or necrosis in post-chemotherapy residuals of seminomatous GCT [17, 18]. Therefore, FDG-PET is recommended to decide whether surveillance or surgical therapy is the treatment of choice in patients with residuals > 3 cm . However, in the setting of a non-seminoma post-chemotherapy mass FDG-PET is not recommended . Although it can detect viable tumour in residual masses, it cannot discriminate mature teratoma from fibrosis or necrosis . Therefore FDG-PET is not helpful to decide if surgical therapy is necessary or not in these patients.
In our case of non-seminomatous GCT, FDG-PET was performed contradictory to standard guidelines prior referral to our centre. Histo-pathological examination revealed that the FDG-avid lesion within the retroperitoneal teratoma represented the papillary renal cell cancer. It has been reported that FDG-PET may have a role in detecting metastasis of renal cancer. However this is usually in the setting of clear cell rather than papillary carcinoma .
Due to the wide spectrum and unpredictability of tumour types that occur in MT, the utility of FDG-PET in the setting of MT remains unknown and requires further investigation. Tissue diagnosis is still the gold standard in determining presence of viable malignancy and discriminating between GCT and other types of tumours.
The occurrence of MT is known to worsen the prognosis of GCT, particularly in metastatic disease [6, 22–24]. One reason for this is that many of the tumours found after MT are highly aggressive (i.e. sarcoma, PNET) [25, 26]. If MT remains undetected, a conventional platinum-based chemotherapy approach may fail in treating the new tumour type developed. This may additionally delay diagnosis of MT and lead to worse outcome [27, 28].
Complete surgical resection, if technically possible, should remain the gold standard of therapy as it will achieve the most reliable histopathologic diagnosis, and has been shown to improve the prognosis of patients with MT in metastatic GCT [2, 3, 6, 27]. If MT is found, histological evaluation is mandatory for all synchronously or metachronously detected metastases. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumour type should be considered [6, 9, 27, 29].
To the best of our knowledge, MT into papillary renal cell carcinoma has not been reported in the setting of metastatic testicular germ cell tumour following platinum-based chemotherapy. Our case highlights the importance of complete surgical resection and histological diagnosis of residual masses after chemotherapy of metastatic non-seminomatous GCTs to allow tailoring of potential subsequent therapies to the transformed tumour type.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal
Germ cell tumour
Primitive neuroectordermal tumour
Beta-human chorionic gonadotropin
Fluorodeoxyglucose positron emission tomography
Renal cell carcinoma antigen
The authors thank Dr. Lih Ming Wong for his editorial assistance.
- Eble JN, Sauter G, Epstein JI, Sesterhenn IA: WHO histological classification of testis tumours, Pathology & Genetics, Tumours of the urinary system and male genital organs. 2004, Lyon: IARC PressGoogle Scholar
- Motzer RJ, Amsterdam A, Prieto V, Sheinfeld J, Murty VV, Mazumdar M, Bosl GJ, Chaganti RS, Reuter VE: Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998, 159: 133-138. 10.1016/S0022-5347(01)64035-7.View ArticlePubMedGoogle Scholar
- Jain D, Sharma MC, Sarkar C, Rishi A, Suri V, Garg A, Mahapatra AK: Spinal teratoma with renal differentiation–a rare phenomenon: report of two patients. Clin Neurol Neurosurg. 2008, 110: 265-269. 10.1016/j.clineuro.2007.09.016.View ArticlePubMedGoogle Scholar
- Comiter CV, Kibel AS, Richie JP, Nucci MR, Renshaw AA: Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol. 1998, 159: 859-863. 10.1016/S0022-5347(01)63754-6.View ArticlePubMedGoogle Scholar
- Mohanty SK, Balani JP, Parwani AV: Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature. Urology. 2007, 70 (812): e817-e810.Google Scholar
- Necchi A, Colecchia M, Nicolai N, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Paolini B, Milani A, Salvioni R: Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU Int. 2011, 107: 1088-1094. 10.1111/j.1464-410X.2010.09705.x.View ArticlePubMedGoogle Scholar
- International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. Edited by: Sobin LH, Gospodarowicz M, Wittekind C. 2009, Wiley: New York, editionEdited by, 7Google Scholar
- International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997, 15: 594-603.Google Scholar
- Korfel A, Fischer L, Foss HD, Koch HC, Thiel E: Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature. Bone Marrow Transplant. 2001, 28: 787-789. 10.1038/sj.bmt.1703212.View ArticlePubMedGoogle Scholar
- Marusic Z, Zovak M, Hagenkord JM, Kash S, Koul MS, Sanger W, Gatalica Z, Kruslin B, Tomas D: Papillary renal cell-like carcinoma in a retroperitoneal teratoma. Pathol Int. 2010, 60: 581-585. 10.1111/j.1440-1827.2010.02559.x.View ArticlePubMedGoogle Scholar
- Kernek KM, Brunelli M, Ulbright TM, Eble JN, Martignoni G, Zhang S, Michael H, Cummings OW, Cheng L: Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. Mod Pathol. 2004, 17: 1309-1313. 10.1038/modpathol.3800195.View ArticlePubMedGoogle Scholar
- Skinnider BF, Amin MB: An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005, 22: 51-68. 10.1053/j.semdp.2005.11.004.View ArticlePubMedGoogle Scholar
- Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT, et al: Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. Int J Cancer. 2008, 123: 569-576. 10.1002/ijc.23565.View ArticlePubMedGoogle Scholar
- Ingold B, Wild PJ, Nocito A, Amin MB, Storz M, Heppner FL, Moch H: Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology. 2008, 52: 674-681. 10.1111/j.1365-2559.2008.03003.x.View ArticlePubMedGoogle Scholar
- Dal Cin P: Genetics in renal cell carcinoma. Curr Opin Urol. 2003, 13: 463-466. 10.1097/00042307-200311000-00007.View ArticlePubMedGoogle Scholar
- Rioja J, Rodriguez-Fraile M, Lima-Favaretto R, Rincon-Mayans A, Penuelas-Sanchez I, Zudaire-Bergera JJ, Parra RO: Role of positron emission tomography in urological oncology. BJU Int. 2010, 106: 1578-1593. 10.1111/j.1464-410X.2010.09510.x.View ArticlePubMedGoogle Scholar
- Becherer A, De Santis M, Karanikas G, Szabo M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K: FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005, 54: 284-288. 10.1016/j.ejrad.2004.07.012.View ArticlePubMedGoogle Scholar
- De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004, 22: 1034-1039. 10.1200/JCO.2004.07.188.View ArticlePubMedGoogle Scholar
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, et al: NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009, 7: 672-693.PubMedGoogle Scholar
- De Santis M, Pont J: The role of positron emission tomography in germ cell cancer. World J Urol. 2004, 22: 41-46. 10.1007/s00345-004-0403-2.View ArticlePubMedGoogle Scholar
- Sacco E, Pinto F, Totaro A, D'Addessi A, Racioppi M, Gulino G, Volpe A, Marangi F, D'Agostino D, Bassi P: Imaging of renal cell carcinoma: state of the art and recent advances. Urol Int. 2011, 86: 125-139. 10.1159/000322724.View ArticlePubMedGoogle Scholar
- Ahmed T, Bosl GJ, Hajdu SI: Teratoma with malignant transformation in germ cell tumors in men. Cancer. 1985, 56: 860-863. 10.1002/1097-0142(19850815)56:4<860::AID-CNCR2820560426>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Rebischung C, Cottu PH, Daban A, Terrier-Lacombe MJ, Theodore C, Bonvalot S, Vallancien G, Culine S: Germ-cell tumours containing non germ-cell neoplasms: teratoma with malignant transformation. Urol Oncol. 2001, 6: 239-242. 10.1016/S1078-1439(01)00133-8. K FView ArticleGoogle Scholar
- Ulbright TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA: The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer. 1984, 54: 1824-1833. 10.1002/1097-0142(19841101)54:9<1824::AID-CNCR2820540910>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Ganjoo KN, Foster RS, Michael H, Donohue JP, Einhorn LH: Germ cell tumor associated primitive neuroectodermal tumors. J Urol. 2001, 165: 1514-1516. 10.1016/S0022-5347(05)66339-2.View ArticlePubMedGoogle Scholar
- Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B: Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009, 33: 1173-1178. 10.1097/PAS.0b013e3181adb9d7.View ArticlePubMedGoogle Scholar
- Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS, Bosl GJ: Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 2003, 21: 4285-4291. 10.1200/JCO.2003.01.019.View ArticlePubMedGoogle Scholar
- Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol. 2008, 26: 595-599. 10.1016/j.urolonc.2007.07.013.View ArticlePubMedPubMed CentralGoogle Scholar
- El Mesbahi O, Terrier-Lacombe MJ, Rebischung C, Theodore C, Vanel D, Fizazi K: Chemotherapy in patients with teratoma with malignant transformation. Eur Urol. 2007, 51: 1306-1311. 10.1016/j.eururo.2006.10.021.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/13/9/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.